Eberhard, Daniel
Balkenhol, Sydney https://orcid.org/0000-0002-8486-7722
Köster, Andrea
Follert, Paula
Upschulte, Eric https://orcid.org/0000-0002-6398-038X
Ostermann, Philipp
Kirschner, Philip https://orcid.org/0000-0002-6711-5959
Uhlemeyer, Celina https://orcid.org/0000-0001-8772-1799
Charnay, Iannis https://orcid.org/0000-0002-0659-7798
Preuss, Christina
Trenkamp, Sandra https://orcid.org/0000-0003-1419-7177
Belgardt, Bengt-Frederik
Dickscheid, Timo
Esposito, Irene
Roden, Michael https://orcid.org/0000-0001-8200-6382
Lammert, Eckhard https://orcid.org/0000-0002-9844-8000
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (La1216/6-1, RTG 2576 vivid, GRK2576, La1216/6-1, IRTG 1902, Priority Program 2041 (SPP 2041), GRK2576, GRK2576, GRK2576)
German Center for Diabetes Research (DZD e.V.); the Federal Ministry of Health, the Ministry of Culture and Science of North Rhine-Westphalia
German Diabetes Center
Studienstiftung des Deutschen Volkes
German Center for Diabetes Research
EC | Horizon 2020 Framework Programme (101147319 (EBRAINS 2.0 Project), „CESYDE“, Grant agreement No. 759099, HORIZON-HLTH-2022-STAYHLTH-02-01: Panel A, INTERCEPT-T2D consortium)
German Center for Diabetes Research (DZD e.V.);the Federal Ministry of Health, the Ministry of Culture and Science of North Rhine-Westphalia
Heinrich Heine University Düsseldorf | Medizinische Fakultät, Heinrich-Heine-Universität Düsseldorf
Hector Foundation (MED2302); German Center for Diabetes Research (DZD e.V.); the Federal Ministry of Health, the Ministry of Culture and Science of North Rhine-Westphalia
Article History
Received: 22 February 2023
Accepted: 7 May 2024
First Online: 14 June 2024
Competing interests
: M.R. receives consultation fees from AstraZeneca, Boehringer Ingelheim, Echosens, Madrigal Pharmaceuticals, MSD Sharp & Dohme, Novo Nordisk, Target RWE. The other authors declare no competing interests.